Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cancer predisposition due to variation(s) in the HAVCR2 gene, which confers the predisposition to susceptibility to subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and hemophagocytic lymphohistiocytosis (HLH). Affected individuals typically present with multiple subcutaneous nodules and systemic B symptoms.
Biomarker and diagnostic research for HAVCR2-related cancer predisposition has been reported in the published literature.
No clinical trials have been registered for HAVCR2-related cancer predisposition.
314 publications have been identified in PubMed for HAVCR2-related cancer predisposition. Kisho has analyzed 217 by research type. Research spans Review / Meta-Analysis (51%), Epidemiology / Natural History (26%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 111 | 51% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 8:12 PM UTC
Common questions about HAVCR2-related cancer predisposition
Disease patterns and progression |
56 |
26% |
Laboratory research | 29 | 13% |
Testing and diagnosis research | 11 | 5% |
Patient case studies | 5 | 2% |
Clinical study results | 2 | 1% |
New treatment approaches | 2 | 1% |
Other research | 1 | 0% |
Robles C (2026). [PMID: 41274764](https://pubmed.ncbi.nlm.nih.gov/41274764/). *Neuroimaging Clin N Am*. [Review / Meta-Analysis]
Gjyrezi A (2026). [PMID: 41428387](https://pubmed.ncbi.nlm.nih.gov/41428387/). *Physiol Rev*. [Review / Meta-Analysis]
Wang L (2026). [PMID: 41106391](https://pubmed.ncbi.nlm.nih.gov/41106391/). *Cell Genom*. [Diagnostic / Biomarker]
Legaki E (2026). [PMID: 41596450](https://pubmed.ncbi.nlm.nih.gov/41596450/). *Int J Mol Sci*. [Review / Meta-Analysis]
Zeng QR (2026). [PMID: 41619888](https://pubmed.ncbi.nlm.nih.gov/41619888/). *International journal of biological macromolecules*. [Review / Meta-Analysis]
Vijayakumar S (2026). [PMID: 41575180](https://pubmed.ncbi.nlm.nih.gov/41575180/). *Immunological reviews*. [Review / Meta-Analysis]
Katabathina VS (2026). [PMID: 42020078](https://pubmed.ncbi.nlm.nih.gov/42020078/). *Radiol Clin North Am*. [Review / Meta-Analysis]
Maura F (2026). [PMID: 41359792](https://pubmed.ncbi.nlm.nih.gov/41359792/). *Blood*. [Review / Meta-Analysis]
Zhang S (2026). [PMID: 41491598](https://pubmed.ncbi.nlm.nih.gov/41491598/). *Molecular cancer*. [Review / Meta-Analysis]
Fu Y (2026). [PMID: 41386230](https://pubmed.ncbi.nlm.nih.gov/41386230/). *Cell genomics*. [Case Report / Case Series]
AI-curated news mentioning HAVCR2-related cancer predisposition
Updated Mar 4, 2026
A new study presents a deep learning approach for predicting the pathogenicity of rare missense variants in cancer predisposition genes. This research could enhance genetic testing and risk assessment for patients with hereditary cancer syndromes.